← All Genmab A/s filings

Genmab A/s Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
GMAB
Genmab A/s
SCHEDULE: Orbis, Allan Gray Boost Genmab Stake to 5.3%
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have collectively increased their beneficial ownership in Genmab A/S to 5.3%, acquiring over 3.3 million shares.
NASDAQ
GMAB
Genmab A/s
SCHEDULE: Orbis Investment Management Discloses Genmab Stake
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly filed a Schedule 13G, reporting beneficial ownership of 5.5% of Genmab A/S common stock as of March 31, 2026.
NASDAQ
GMAB
Genmab A/s
SCHEDULE: Orbis, Allan Gray Disclose 6.6% Stake in Genmab A/S
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd jointly reported a 6.6% beneficial ownership stake in Genmab A/S common stock.
NASDAQ
GMAB
Genmab A/s
SCHEDULE: Orbis, Allan Gray Disclose 5.8% Stake in Genmab A/S
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5.8% beneficial ownership stake in Genmab A/S common stock.
NASDAQ
GMAB
Genmab A/s
SCHEDULE 13G/A: BlackRock Discloses 5.6% Stake in Genmab A/S Common Stock
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Genmab A/S as of March 31, 2025.